CBI2026 Nucleic Acid Therapeutics Innovation Conference: Advancing mRNA and Small Nucleic Acid Drug Development

Formerly served as a graduate supervisor at the Beijing Institute of Genomics, Chinese Academy of Sciences; Principal Investigator of the Ministry of Science and Technology’s “Innovation 2020” Vaccine Project; Chief Scientist for the National 13th Five-Year Plan Major Special Project on Infectious Diseases. Participated in the 11th Five-Year Plan Major Special Project on Drug R&D; led projects under the 12th and 13th Five-Year Plans for the “Major New Drug” Creation Initiative. Currently conducting multiple research projects funded by the Ministry of Science and Technology and local science and technology commissions. Serves as a review expert for the National Natural Science Foundation of China and provincial natural science foundations in Zhejiang, Fujian, and other provinces; serves on the editorial boards of several journals; has published more than 60 SCI-indexed papers. The Qichensheng team has over ten years of experience in investigator-initiated exploratory clinical studies in the field of cancer vaccines.

Lu Hang is the CEO of Jiayi Biotech, which focuses on the innovative development and industrialization of biopharmaceutical products based on mRNA technology and antibody platforms, and has established a development platform for preventive and therapeutic biological products.

Dr. Lu Hang has worked at EBSI and Merck in the United States for over 20 years, serving as Director or Chief Scientist. As a technical leader or core team member, he has been responsible for multiple stages of the full lifecycle development of more than ten traditional and next-generation vaccine and biological products, including CYFENDUS, which received FDA approval in 2023.

Lu Hang is an advisor to the Vaccine Basic Research Professional Committee of the China Vaccine Industry Association, former president of the Chinese Biopharmaceutical Association (CBA), and president of CBA-China.

Dr. Weiwei Tian currently serves as Vice President of R&D at Sinocan Group and General Manager of Sinocan Pharmaceuticals (Suzhou). His research primarily focuses on the creation of novel small interfering nucleic acid drugs and the development of delivery technologies. He earned his Ph.D. in Organic Chemistry from the University of Delaware in the United States and conducted pharmaceutical-related research at The Scripps Research Institute (TSRI) in the U.S. and the Agency for Science, Technology and Research (A*STAR) in Singapore.

Mr. Zhuocheng Tu has over nine years of experience in investment banking and private equity investment. He previously worked at Fengchuan Capital, where he led and participated in investments in life and health projects. Prior to joining Fengchuan Capital, Mr. Tu served in the Investment Banking Departments of China International Capital Corporation (CICC) and Haitong International, participating in various projects including initial public offerings (IPOs) and mergers and acquisitions (M&A) for multiple companies listed on the A-share, Hong Kong, and U.S. stock markets. Mr. Tu holds a Bachelor’s degree in Economics from Shanghai University of Finance and Economics.

Dr. Li Wang, who holds a Ph.D. in Immunology and graduated from the Academy of Military Medical Sciences, currently serves as Vice General Manager of Xuanzhu Biotechnology Co., Ltd. She oversees business units including small nucleic acid development, clinical development, and business development. With over 15 years of experience in new drug development and related fields, she possesses comprehensive expertise in managing the entire drug development lifecycle, from early-stage research and project initiation to commercialization. Long committed to the research and development of novel therapeutics for major diseases such as cancer and metabolic disorders, she has played a pivotal role in building the company’s innovative drug pipeline, advancing clinical development, and driving business expansion. Dr. Wang has led the R&D efforts for multiple innovative drugs at Xuanzhu Biotechnology, facilitating the market approval of three innovative drugs across multiple indications and securing overseas licensing deals. She brings extensive experience in project initiation, formulation of differentiated development strategies, execution of preclinical and clinical development, and out-licensing/collaborative partnerships.

He Wenjun, General Manager of the Chromatography Division at Weichun Biotechnology (Guangzhou) Co., Ltd., is a seasoned professional in the scientific instrumentation industry.

Holds a Master’s degree in Medicinal Chemistry from the Chinese Academy of Sciences, with nearly a decade of experience in scientific instrument market development. Has deep expertise in the chromatography industry, combining solid technical proficiency with strong business acumen.

Proficient in technology-driven sales, with the ability to accurately identify customer pain points in chromatographic analysis and provide tailored solutions. Possesses team management experience and excels at leading teams to achieve high-performance targets. Committed to advancing the market adoption of domestically produced scientific instruments and consumables through professional product expertise and efficient marketing strategies.

— Master’s degree from Peking University Health Science Center; MBA from Harvard University.

— Formerly served as Deputy Director of the Beijing Product Design Center of Taiji Group, and Secretary of the Board of Directors of the Taiji Anti-Cancer Science Foundation,

— Joined 3D Medicines in 2016, successively serving as Head of Regulatory Affairs and Deputy General Manager.

— Member of the Hong Kong Investor Relations Association; Member of the 4th Pharmaceutical Innovation Investment Professional Committee of the China Pharmaceutical Innovation and R&D Association (PhIRDA).

Dr. Xiong Changyun holds a Ph.D. from the Shanghai Institute of Biochemistry, Chinese Academy of Sciences, and completed his postdoctoral fellowship at the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH). He has previously held positions at renowned pharmaceutical companies including BD, Novartis, Amgen, and Aim Vaccine. Currently, he is the Founder and CEO of Ningbo Junjian Biotech. With over two decades of experience in the biopharmaceutical industry, Dr. Xiong has led the research, development, and industrialization of multiple COVID-19 vaccines and antibody drugs, with a focus on self-amplifying mRNA technology. He has published more than 20 academic papers and holds over 20 invention patents, specializing in end-to-end biologic drug development, process scale-up, and commercialization.

B.S. in Pharmacy, West China University of Medical Sciences (1992); M.S. in Neuropsychopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (1995); Ph.D. in Neuropsychopharmacology, Baylor College of Medicine, USA (2000); Postdoctoral Fellow, Department of Neurobiology, Duke University, USA (2000–2003). Currently Senior Investigator at the Center for Excellence in Brain Science and Intelligence Technology/Institute of Neuroscience, Chinese Academy of Sciences, and Shanghai Research Center for Brain Science and Brain-Inspired Intelligence; Distinguished Professor at the University of Chinese Academy of Sciences, ShanghaiTech University, and Shanghai Jiao Tong University. Standing Director of the Chinese Society for Neuroscience; Vice Chair of the Basic and Clinical Neurology Branch and the Basic and Clinical Psychiatry Branch of the Chinese Society for Neuroscience; Standing Committee Member of the Pharmacotherapy Committee of the China Anti-Epilepsy Association. Research interests include elucidating mechanisms of neurological disorders and developing innovative therapeutics, as well as establishing non-human primate models of brain diseases, objective biomarkers, and evaluation paradigms. Author of over 100 peer-reviewed publications and holder of more than 20 granted patents.

Ph.D. in Medical Genetics from Uppsala University, Sweden; Postdoctoral Fellow in Cancer Genetics and Neurogenetics at the University of California, San Francisco/Los Angeles; Former Research Fellow in the Division of Rheumatology, Department of Medicine, School of Medicine, University of California, San Diego. Upon returning to China, appointed as Qianjiang Scholar Distinguished Professor and Researcher at Shenzhen Research Institute of Sun Yat-sen University. Currently serves as Industry Professor at the Center for Cell and Gene Therapy Research, Southern University of Science and Technology. Founder of Ruimeiona (Guangzhou) Biopharmaceutical Technology Co., Ltd., with long-term engagement in the research and development of cancer genomics, cancer mRNA vaccines, and large RNA models.

Dr. Xudong Yuan is the Founder and CEO of ACON Pharma. He earned his Ph.D. in Pharmaceutics from the College of Pharmacy at the University of Georgia in the United States. After graduation, he served at Nova Southeastern University and the LIU College of Pharmacy, engaging in pharmaceutical research for many years, with a particular focus on nucleic acid drug delivery systems. Dr. Yuan subsequently transitioned from academia to the pharmaceutical industry, holding various positions as a pharmaceutical scientist at Johnson & Johnson, RB, and GlaxoSmithKline, where he participated in the research and product development of different drug dosage forms and modified-release technologies. He also served as Research Director and Vice President at pharmaceutical companies in New Jersey and Philadelphia, primarily overseeing the development of complex formulations such as liposomal, nanoparticle, nanocrystal, and microsphere-based injectables, as well as ophthalmic solutions and nasal sprays. In these roles, he was fully responsible for the R&D, manufacturing, and regulatory submission of drug products. In 2020, Dr. Yuan founded ACON Pharma, which focuses on the research and development of siRNA and mRNA nucleic acid therapeutics and complex drug delivery systems.